A Retrospective Evaluation of the Intraocular Pressure Spikes With Loteprednol and Loteprednol/Tobramycin

Study Identifier
MA-RES-08-003
CT.gov Identifier
NCT00834171
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Study Details

Medical Condition
  • Ocular Hypertension
    • Study Drug
  • Loteprednol etabonate ophthalmic suspension 0.5%
  • Loteprednol etabonate (0.5%) and tobramycin (0.3%).
    • Phase
    N/A
    Sex
    Female & Male
    Age
    18+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * Any patient who experienced an IOP spike while using Lotemax or Zylet will be included
    Exclusion Criteria:
    * N/A

    Protocol Summary

    Patient charts will be reviewed to evaluate the incidence of intraocular pressure spikes while on Loteprednol etabonate ophthalmic suspension 0.5%, Loteprednol etabonate (0.5%) and tobramycin (0.3%)

    Study Locations

    Location
    Status
    Location
    Maclean, Virginia, United States
    Status
    Not applicable